Synthroid Holding 75% Of Its Pre-Generic Script Share, Abbott Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Script share for the levothyroxine brand is "within our range of expectations" since AB-rated generics entered the market, CFO Freyman says. Abbott predicted generic erosion for Synthroid would be less than that for other drugs due, in part, to the product's narrow therapeutic range.